Open Heart Surgery News and Research

RSS

FDA approves new artificial heart valve device that does not require major open surgery

An artificial heart valve device that does not require major open surgery has been approved by the Food and Drug Administration.

From Medtronic 5 Feb 2014

Sanford Hospital starts clinical trial to study dissolving device in patients with CAD

Sanford Heart Hospital has started a clinical trial to study a dissolving device in patients with coronary artery disease. The ABSORB III clinical trial will investigate the safety and effectiveness of the Absorb Bioresorbable Vascular Scaffold (BVS) device, manufactured by global health care company Abbott.

4 Feb 2014

New vacuum-like tool removes potentially deadly, large clots in hearts

Instead of making a chest incision for open heart surgery, cardiovascular surgeons can now use a new vacuum-like tool to remove potentially deadly, large clots that lodge in patients' hearts.

29 Jan 2014

Gagnon Cardiovascular Institute adopt new medical device to treat patients with severe aortic stenosis

The Gagnon Cardiovascular Institute at Morristown Medical Center today became the first hospital in the tri-state area to adopt a new minimally invasive medical device to treat patients with severe aortic stenosis who are too ill or frail to have their aortic valves replaced trough traditional open-heart surgery.

25 Jan 2014

BIDMC receives FDA approval to use new medical device in patients with severely damaged aortic heart valves

Beth Israel Deaconess Medical Center (BIDMC) yesterday became the first institution in the United States to use a new minimally invasive medical device since it received FDA approval last week.

From Medtronic 24 Jan 2014

MicroPort Scientific, Sorin Group form joint venture to market CRM devices in China

MicroPort Scientific Corporation and Sorin Group, announced today that they have entered into a definitive agreement to form a joint venture to market and develop cardiac rhythm management devices (implantable pacemakers, defibrillators, cardiac resynchronization devices and related devices) in China. MicroPort will hold a 51 percent stake in the joint venture entity, while Sorin will hold the remaining 49 percent interest.

9 Jan 2014

New technology could dramatically reduce number of open-heart surgeries

Researchers at the University of Waterloo have developed a new technology that could dramatically reduce the number of open-heart surgeries for people with pacemakers.

18 Dec 2013

INTENSIA family of ICDs and CRT-D devices receive CE mark approval

Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced today that the INTENSIA family of implantable cardioverter defibrillators and cardiac resynchronization therapy devices received CE (Conformité Européenne) mark approval. This family of devices includes the single-chamber INTENSIA VR, the dual-chamber INTENSIA DR and the INTENSIA SonR® CRT-D devices, all of which feature a DF-4 high voltage connector.

6 Dec 2013

U.S. physicians use CSI's Diamondback 360 Coronary OAS for coronary artery disease treatment

Cardiovascular Systems, Inc., today announced that its new Diamondback 360 Coronary Orbital Atherectomy System is being used by physicians across the country to treat coronary artery disease. This follows the company's recent PMA approval from the U.S. Food and Drug Administration to market the device as a treatment for severely calcified coronary arteries.

3 Dec 2013

Nearly 1% of all newborns in Switzerland diagnosed with congenital heart defect

Approximately one percent of all newborns in Switzerland are diagnosed with a congenital heart defect, roughly half of them require open heart surgery. Most children, including those with the most severe heart defects, survive because of the significant advancements in surgical techniques. Therefore, the current research focuses less on survival than on long-term consequences and quality of life of these children.

2 Dec 2013

Sorin Group receives CE Mark approval for Solo Smart stentless aortic valve

Sorin Group, a global medical company and a leader in the treatment of cardiovascular diseases, announced today that it has received CE Mark approval for the Solo Smart stentless aortic valve.

23 Nov 2013

MICS CABG procedure safe and feasible, confirms new study

A new study published by The Journal of Thoracic and Cardiovascular Surgery confirms MICS CABG (minimally invasive cardiac surgery/coronary artery bypass grafting) is a safe and feasible procedure that ensures positive outcomes. Published on Nov 1st, the article brings light to the open-heart surgery alternative pioneered by Medical Director and cardiothoracic surgeon, Joseph T. McGinn of The Heart Institute at Staten Island University Hospital.

20 Nov 2013

New procedure repairs the mitral valve in patients at high risk for open heart surgery

A minimally invasive procedure is the first effective treatment for patients who are high risk for standard open heart surgery for a leaking heart valve, a study led by a University of Virginia School of Medicine researcher has found.

14 Nov 2013

Cycling champion Cadel Evans takes part in cutting edge cardiopulmonary research

As the first Australian to win the Tour de France, cycling champion Cadel Evans has already pedalled his way into our hearts. Now he is taking part in world-leading cardiopulmonary research – by pedalling inside an MRI scanner.

11 Nov 2013

Landmark clinical trial of artificial aortic heart valve shows positive results

Loyola University Medical Center is the only Chicago hospital participating in a landmark clinical trial of an artificial aortic heart valve that does not require open heart surgery.

From Medtronic 8 Nov 2013

Current percutaneous techniques shed light on treatment of heart valve leakage

A Paravalvular regurgitation, or leakage, commonly affects valvular prostheses, particularly artificial valves placed percutaneously according to data presented at the 2013 Transcatheter Cardiovascular Therapeutics (TCT) conference.

4 Nov 2013

Canadian discovery could lead to development of vaccine against Epstein-Barr virus

Development of a vaccine against Epstein-Barr virus has taken a step forward with the Canadian discovery of how EBV infection evades detection by the immune system.

12 Oct 2013

Bluhm Institute enrolls first patient in SALUS trial to evaluate movable, non-metallic heart valve

Northwestern's Bluhm Cardiovascular Institute has enrolled its first participant in SALUS, a clinical trial studying the effectiveness of a prosthetic aortic heart valve that can be placed without open-heart surgery.

10 Oct 2013

FDA approves revised labeling for Sapien Transcatheter Heart Valve

The U.S. Food and Drug Administration today approved revised labeling for the Sapien Transcatheter Heart Valve, making the device available to an expanded group of patients who have inoperable aortic valve stenosis, a disease of the heart valves that causes narrowing of the aortic valve, restricting blood flow from the heart.

24 Sep 2013

Women are 25% less likely to die post TAVI than men, says doctor

Dr Sherif said: "Earlier studies on the impact of gender on outcome after transcatheter aortic valve implantation (TAVI) have had conflicting results. A Canadian study reported in 641 consecutive patients that female sex is associated with a better long-term and short-term survival after TAVI.1 An Italian study of 305 high risk patients found no gender differences in composite safety and efficacy endpoints at 30 days and one year after TAVI."2

2 Sep 2013